Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Phase 2
37
about 11 years
18+
1 site in NY
What this study is about
This trial is testing a treatment with intra-arterial Cetuximab and reirradiation for patients whose brain cancer has returned after other treatments. The goal is to see if this approach can help prevent the cancer from growing back.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Hypofractionated re-irradiation
- 2.Take Intra-arterial Cetuximab
- 3.Take Intra-arterial Mannitol
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ALIMENTARY TRACT AND METABOLISM
injection (Injection)
Primary: Overall Survival (OS), Progression Free Survival (PFS)
Secondary: Composite overall response rate (CORR) through the Response Evaluation Criteria In Solid Tumors (RECIST), Toxicities graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03
radiation
Oncology